Vlado Perkovic's Publications

• Causes of death in patients with chronic kidney disease: insights from the ASCEND-D and ASCEND-ND cardiovascular outcomes trials

  Journal articles

  2022

  European Heart Journal

• Baseline cardiovascular risk in subjects with type 2 diabetes and chronic kidney disease from the FLOW trial

  Journal articles

  2022

  European Heart Journal

• Differing approaches to analyse on-treatment cardiovascular events comparing daprodustat with darbepoetin: results from the ASCEND-ND trial

  Journal articles

  2022

  European Heart Journal

• EFFICACY AND SAFETY OF REDUCED-DOSE ORAL METHYLPREDNISONE IN IGA NEPHROPATHY: THE TESTING TRIAL

  Conference Abstracts

  2022

  NEPHROLOGY

• CANAGLIFLOZIN AND DIURETIC USE IN TYPE 2 DIABETES AND CHRONIC KIDNEY DISEASE: INSIGHTS FROM THE CREDENCE TRIAL

  Conference Abstracts

  2022

  NEPHROLOGY

• Canagliflozin and atrial fibrillation in type 2 diabetes mellitus: A secondary analysis from the CANVAS Program and CREDENCE trial and meta-analysis

  Journal articles

  2022

  Diabetes, Obesity and Metabolism

• Oral Methylprednisolone and Decline in Kidney Function or Kidney Failure in Patients with IgA Nephropathy - Reply

  Journal articles

  2022

  JAMA

• Initiation of the SGLT2 inhibitor canagliflozin to prevent kidney outcome guided by HbA(1c) and predicted risk of kidney failure

  Conference Abstracts

  2022

  DIABETOLOGIA

• Novel subgroups of patients with type 2 diabetes show differential cardiovascular and kidney benefits with canagliflozin: a data-driven proteomic cluster analysis

  Conference Abstracts

  2022

  DIABETOLOGIA

• Blood pressure-lowering treatment for prevention of major cardiovascular diseases in people with and without type 2 diabetes: an individual participant-level data meta-analysis

  Journal articles

  2022

  The Lancet Diabetes and Endocrinology

• Effect of Canagliflozin on Total Cardiovascular Burden in Patients With Diabetes and Chronic Kidney Disease: A Post Hoc Analysis From the CREDENCE Trial

  Journal articles

  2022

  Journal of the American Heart Association

• Fasting Substrate Concentrations Predict Cardiovascular Outcomes in the CANagliflozin cardioVascular Assessment Study (CANVAS)

  Journal articles

  2022

  Diabetes Care

• Rationale, design, demographics and baseline characteristics of the randomized, controlled, Phase 2b SAPPHIRE study of verinurad plus allopurinol in patients with chronic kidney disease and hyperuricaemia

  Journal articles

  2022

  Nephrology Dialysis Transplantation

• Platform Clinical Trials Within NephrologyInterpreting the Evidence

  Journal articles

  2022

  American Journal of Kidney Diseases

• Increase in BNP in Response to Endothelin-Receptor Antagonist Atrasentan Is Associated With Incident Heart Failure

  Journal articles

  2022

  JACC: Heart Failure

• The impact of canagliflozin on the risk of neuropathy events: A post-hoc exploratory analysis of the CREDENCE trial

  Journal articles

  2022

  Diabetes and Metabolism

• Baseline Characteristics of Subjects in the Once-Weekly (OW) Semaglutide FLOW Kidney Outcomes Trial

  Conference Presentations

  2022

• Interleukin-6 and Cardiovascular Outcomes in Patients with Type 2 Diabetes: A Post Hoc Analysis of CANVAS Trial

  Conference Abstracts

  2022

  DIABETES

• Efficacy and Safety of Daprodustat for Treatment of Anemia of Chronic Kidney Disease in Incident Dialysis Patients: A Randomized Clinical Trial

  Journal articles

  2022

  JAMA Internal Medicine

• Cardiovascular and renal outcomes with canagliflozin in patients with peripheral arterial disease: Data from the CANVAS Program and CREDENCE trial

  Journal articles

  2022

  Diabetes, Obesity and Metabolism

• Impact of random variation in albuminuria and estimated glomerular filtration rate on patient enrolment and duration of clinical trials in nephrology

  Journal articles

  2022

  Diabetes, Obesity and Metabolism

• BASELINE CHARACTERISTICS OF THE FLOW TRIAL POPULATION: KIDNEY OUTCOMES TRIAL WITH ONCE-WEEKLY SEMAGLUTIDE IN PEOPLE WITH TYPE 2 DIABETES AND CHRONIC KIDNEY DISEASE

  Conference Papers

  2022

  NEPHROLOGY DIALYSIS TRANSPLANTATION

• Effect of Oral Methylprednisolone on Decline in Kidney Function or Kidney Failure in Patients With IgA Nephropathy: The TESTING Randomized Clinical Trial

  Journal articles

  2022

  JAMA - Journal of the American Medical Association

• Sodium-Glucose Cotransporter 2 Inhibitors and Risk of Hyperkalemia in People with Type 2 Diabetes: A Meta-Analysis of Individual Participant Data from Randomized, Controlled Trials

  Journal articles

  2022

  Circulation

• FC 123: Baseline Characteristics of the Flow Trial Population: Kidney Outcomes Trial With Once-Weekly Semaglutide in People With Type 2 Diabetes and Chronic Kidney Disease

  Conference Abstracts

  2022

  Nephrology Dialysis Transplantation

• Study design and baseline characteristics of patients on dialysis in the ASCEND-D trial

  Journal articles

  2022

  Nephrology Dialysis Transplantation